Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lofepramine/phenylalanine - MultiCell Technologies

Drug Profile

Lofepramine/phenylalanine - MultiCell Technologies

Alternative Names: L-phenylalanine/Lofepramine; LAX-202; Lofepramine/L-phenylalanine; MCT-125; Phenylalanine/lofepramine

Latest Information Update: 03 Sep 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Unknown
  • Class Dibenzazepines; Essential amino acids; Neuropsychotherapeutics; Tricyclic antidepressants
  • Mechanism of Action Adrenergic uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Fatigue

Most Recent Events

  • 03 Sep 2015 Lofepramine/phenylalanine is still in phase-II development for Fatigue
  • 02 Nov 2010 MultiCell receives Qualifying Therapeutic Discovery Project grant under the Patient Protection and Affordable Care Act of 2010 (PPACA) for MCT 125 development in Fatigue
  • 03 Jan 2006 Data from a media release have been added to the Neurological Disorders therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top